Teva Pharmaceuticals News and Resources

Podcast

Teva’s Drug Development Pivot: How Strategic Partnerships Are Driving Growth

“The greatest opportunity at Teva is our innovative pipeline. We’re really leaning in on our innovative pipeline as an integral part of our pivot to growth strategy.” This is the ambitious vision of Dr Eric Hughes, Executive Vice President of

26 August 2025

CDMO News

Teva Pharmaceuticals Partners with mAbxience for New Anti-PD-1 Oncology Biosimilar

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has announced a new global licensing agreement with mAbxience, a Fresenius Kabi majority-owned group. This agreement focuses on the development of an anti-PD-1 oncology biosimilar candidate. It is the

7 October 2024

Teva Pharmaceuticals News and Resources

Teva’s Drug Development Pivot: How Strategic Partnerships Are Driving Growth

Teva Pharmaceuticals Partners with mAbxience for New Anti-PD-1 Oncology Biosimilar

Welcome to PharmaSource

Follow us

Top Links

Get in touch